Document is current
Any future updates will be listed below
-
Authors
Adler, Benjamin A. https://orcid.org/0000-0002-7488-3040
Hessler, Tomas
Cress, Brady F. https://orcid.org/0000-0002-2948-2846
Lahiri, Arushi
Mutalik, Vivek K. https://orcid.org/0000-0001-7934-0400
Barrangou, Rodolphe https://orcid.org/0000-0002-0648-3504
Banfield, Jillian https://orcid.org/0000-0001-8203-8771
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
U.S. Department of Energy
- License Information
-
More Information
Article History
Received: 23 March 2022
Accepted: 23 September 2022
First Online: 31 October 2022
Competing interests
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences; a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, The Column Group and Inari; a director at Johnson & Johnson and Tempus; and has research projects sponsored by Biogen, Pfizer, AppleTree Partners and Roche. J.B. is a founder of Metagenomi. R.B. is a shareholder of Caribou Biosciences, Intellia Therapeutics, Locus Biosciences, Inari, TreeCo and Ancilia Biosciences. V.K.M. is a co-founder of Felix Biotechnology. All other authors declare no competing interests.
